Navigation Links
Study examines radiation dose estimates for pregnant women undergoing therapeutic ERCP
Date:4/28/2009

thod for the assessment of the fetal dose from ERCP procedures. Researchers examined 24 consecutive male and non-pregnant female patients who received therapeutic ERCP for conditions including cholangitis, choledocholithiasis, pancreatitis, stent extraction, and pancreatic and bile-duct tumors. It should be emphasized that none of these patients were pregnant or suspected of being pregnant, thus no measures to limit radiation exposure were taken. Based on the radiation exposure in these 24 non-pregnant patients, the radiation dose delivered to a theoretical fetus was then estimated. The estimation was performed using a Monte-Carlo-N-particle transport code, widely used to assess radiation dose distribution in the body by simulating radiologic examinations in mathematical phantoms.

Results

The radiation doses estimated for a theoretical fetus in these 24 ERCP procedures ranged from 3.4 to 55.9 mGy. The researchers provide tabulated data that then allow for calculation of the fetal radiation dose.

The data revealed that the fetal dose from ERCP procedures may occasionally exceed 10 mGy, a considerably greater value than previously reported. In cases with pregnant patients, special efforts should be made to minimize the fetal radiation burden. An accompanying editorial on this study by former ASGE Standards of Practice Committee Chair Todd H. Baron, MD, FASGE, division of gastroenterology and hepatology, and Beth A. Schueler, PhD, department of radiology, both from the Mayo Clinic College of Medicine, Rochester, Minn., appears in the April issue and offers a list of general rules for safe and effective fluoroscopy use to minimize radiation exposure during ERCP in pregnant women.

Researchers noted that limitations of the study included a source of error in the estimation of the fetal dose related to variations of fetus location and size from the average, especially during the second and third trimesters. Another limitation conc
'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. New Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
2. Post-marketing Study of Smartlipo Procedure by Juva Skin Reveals Significant Skin Tightening
3. FSU researcher wins $2.2 million grant to study childhood obesity
4. New Study Shows Supplementing With Probiotics May Ease Anxiety
5. Study to Document Billions in Annual Health Care Savings From Group Purchasing Organizations That Could Play Bigger Role in Obama Health Care Reform
6. MCG participating in national study to identify genetic variants in schizophrenia
7. Prostate Study Shows BOTOX May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia
8. Aderans Research Launches Second Phase of Hair Loss Study
9. Packard/Stanford study suggests two causes for bowel disease in infants
10. Major statin study reveals several important findings for reducing prostate cancer and disease
11. Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... Royal River Natural ... study that followed men and women for 19 years and found that, among those ... not take multivitamins. , The report is part of the September 2015 issue of ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... D.O., has joined its medical management team as an Associate Medical Director. ... sizes and types in the U.S. and abroad. , Dr. Nelson has ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Two of Washington ... cultural relations through food and dining. , Recently named “the next big thing” ... Diotaiuti are known for telling the whole story behind food and reclaiming culinary traditions ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, tax, ... named a “Best of the Best” firm in the U.S., as well as being ... of the Best” in the U.S., selected exclusively on performance in specific areas of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Kit is now available. With the Connectivity Kit, EasySampler data is ... jacketed lab reactor control experiment, on a touchscreen platform. , EasySampler fully ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... Northeast, and boys are at higher risk than girls, study ... sweeping government study of childhood cancers has found numerous differences ... and where he or she lives in the United States. ... cancers, the researchers found, and youngsters in the Northeast were ...
... June 2 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) ... its lead anticancer agent Cloretazine(R) (VNP40101M) in,combination with cytarabine ... had been presented at the 44th Annual Meeting of,the ... The Phase III trial started in March 2005 ...
... (ASCO) ... Annual Meeting -, IRVINE, Calif., June 2 ... an analysis from the,Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The results,suggest ... reduction in the risk of death in newly diagnosed,patients with metastatic osteosarcoma, ...
... Marketing and, Communications Professionals for Inspiring Tales of Patient and ... ... EL SEGUNDO, Calif., June 2 DaVita Inc., a leading,provider ... failure (CKD), today announced that the company,s internal,publication, DaVita Magazine: Stories ...
... BETHESDA, Md., June 2 /Xinhua-PRNewswire/ -- Chindex ... Western healthcare,services and products in the People,s ... division, United Family Healthcare (UFH), responded to,the ... personnel,and other in- kind donations., Roberta ...
... the overall rate of high school baseball-related injuries has ... injuries that occur has increased, according to a new ... Research and Policy (CIRP) of The Research Institute at ... estimated 132,000 high school baseball-related injuries occurred with an ...
Cached Medicine News:Health News:U.S. Childhood Cancers Vary by Sex, Region 2Health News:U.S. Childhood Cancers Vary by Sex, Region 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 3Health News:Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 2Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 3Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 4Health News:IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE) 5Health News:DaVita Magazine Takes Home Two Prestigious Hermes Creative Awards 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 2Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 3Health News:Chindex and United Family Healthcare Respond to Sichuan Earthquake Disaster 4Health News:Injuries to high school baseball players becoming more serious 2
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
(Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: